Traders should monitor the March 31 conference call for actual financial results and any updates on clinical trial progress, especially enrollment status in OVATION 3, which could influence investor sentiment.
Price Chart
Executive Summary
Imunon, Inc. announced it will host a conference call on March 31, 2026, to discuss its 2025 financial results and provide a clinical update on its lead candidate, IMNN-001, currently in Phase 3 for advanced ovarian cancer. No actual financial data was released in this press release, only the announcement of an upcoming earnings call.
Key Facts
- Imunon will host a conference call on March 31, 2026, at 11:00 a.m. EDT to discuss 2025 financial results and clinical updates.
- No financial results or clinical data were disclosed in this press release.
- The company is advancing IMNN-001, a DNA-based IL-12 immunotherapy, in a Phase 3 trial (OVATION 3) for advanced ovarian cancer.
- Dosing completed in a first-in-human study of its COVID-19 booster vaccine, IMNN-101.
Financial Impact
None disclosed — financial results not released
Risk Factors
- No material data provided in this release — potential for disappointment if upcoming results are weak.
- Clinical-stage biotech risk: Phase 3 trial outcomes are uncertain and subject to failure despite prior Phase 2 data.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261137 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $1.19 | awaiting T+5 | — | $1.23 (+3.36%) |
Sep 29, 2026 27d ago | 8-K | $1.34 $1.12 | ▲ +16.10% | ▲ +18.05% | $1.23 (+7.87%) |
Aug 11, 2026 10w ago | 8-K | $1.61 $1.58 | ▼ −1.86% | ▼ −1.42% | $1.23 (−23.60%) |
Aug 11, 2026 10w ago | 8-K | $1.61 $1.58 | ▼ −1.86% | ▼ −1.46% | $1.23 (−23.60%) |
Jun 30, 2026 16w ago | 8-K | $1.88 $1.95 | ▲ +3.72% | ▲ +3.46% | $1.23 (−34.57%) |
Jun 16, 2026 18w ago | 8-K | $1.86 $1.73 | ▼ −6.99% | ▼ −5.95% | $1.23 (−33.87%) |
Jun 4, 2026 20w ago | 8-K | $2.10 $2.03 | ▲ +3.33% | ▲ +0.78% | $1.23 (+41.43%) |
May 12, 2026 23w ago | 8-K | $2.70 $2.26 | ▼ −16.30% | ▼ −16.37% | $1.23 (−54.44%) |
May 4, 2026 25w ago | 8-K | $2.80 $2.73 | ▼ −2.50% | ▼ −5.44% | $1.23 (−56.07%) |
Mar 31, 2026 29w ago | 8-K | $2.94 $3.13 | ▲ +6.46% | ▲ +2.52% | $1.23 (−58.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers